Citations

Clear

112 citation(s) found for "Fasching, PA".

Abstract 225: Tumor-infiltrating CD8-positive T-lymphocytes in tubo-ovarian high-grade serous cancer are associated with multiple germline variants in 22q12.1 in a genome-wide association analysis
Natanzon, Yanina , Armasu, Sebastian M. , McCauley, Bryan M. , Cunningham, Julie M. , Chang‐Claude, Jenny, Fasching, Peter A. , Goodman, Marc T. , Moysich, Kirsten B. , Ness, Roberta B., Goode, Ellen L. , Goodman, Marc T , Köbel, Martin , Winham, Stacey J. , Vierkant, Robert A. , Bowtell, David D.L. , Campbell, Ian , DeFazio, Anna , Karlan, Beth Y. , Modugno, Francesmary , Sieh, Weiva , Pharoah, Paul D.P. , Ramus, Susan J.

Mayo Clinic

Cancer Research | August 17, 2018 | Volume: 78 | Issue: 13_Supplement | Pages: 225-225

10.1158/1538-7445.am2018-225 Get It

Abstract Tubo-ovarian high-grade serous cancer (HGSC) is the most common histotype of epithelial ovarian cancer (70%-80%) and the leading cause of death from gynecological malignancy. Novel monoclonal antibody and adoptive cell transfer immunotherapies have found success in cancer in the past five years; however success in HGSC treatment has been elusive thus far. We have recently shown that CD8+ T-lymphocytes infiltrating the tumor proper (TILs) associate in a dose response manner with longer patient survival time regardless of age, stage or residual disease. As understanding host factors associated with this clinically relevant tumor phenotype will contribute to the development of targeted therapies, we sought to identify germline genetic factors associated with CD8+ TIL levels in HGSC. We performed a germline genome-wide association study (GWAS) of CD8+ TILs using 1204 HGSC patients of European ancestry from twelve studies with centralized genotyping, immunohistochemistry, and harmonization of clinical data. Germline genotypes were assayed using the Illumina Infinium OncoArray Beadchip and were imputed to over 11.4 million variants based on the 1000 Genomes Project reference panel. CD8 immunohistochemistry was performed on tissue microarrays using the Leica Bond Rx stainer and scored into four levels of CD8+ TILs per x400 magnification of a 0.55-mm diameter field for each tumor hotspot: none (no CD8+ TILs), low (1-2 CD8+ TILs), moderate (3-19 CD8+ TILs), high (20 or more CD8+ TILs). GWAS used multinomial regression modelling of these four CD8+ TIL levels adjusted for study site, age, and European ancestry principal components. On the average, CD8+ TIL levels were 18%, 19%, 44% and 18% for none, low, moderate and high levels, respectively. As expected, CD8+ TIL levels associated with overall survival time (p < 2.6x10-8), and CD8+ TIL levels and age at diagnosis were similarly distributed across study sites. We identified a region on chromosome 22 with multiple, correlated variants (MAF > 20%) associated with CD8+ TIL levels at p-value < 2.0x10-5. The most statistically significant variant was an indel (rs557925408) located in the an intron of the MYO18B gene (Myosin XVIIIB, p-value < 8.7x10-6). Each copy of this variant associated with a reduced extent of CD8+ TIL infiltration (OR low v none = 0.92; OR moderate v none = 0.61). An independent set of 1200 OncoArray genotyped HGSC cases are undergoing CD8+ TIL scoring in December 2017 and will be included in final genome-wide analysis. This will provide improved statistical power and enable consideration of additional genetic models (e.g., linear trend tests). Comprehensive integrative analysis of germline, tumor, and clinical features provides a model for clinical molecular epidemiology studies and will be key to increasing our understanding of this important HGSC immunophenotype. Citation Format: Yanina Natanzon, Martin Köbel, Stacey J. Winham, Sebastian M. Armasu, Bryan M. McCauley, Robert A. Vierkant, Julie M. Cunningham, David Bowtell, Ian G. Campbell, Jenny Chang-Claude, Anna deFazio, Peter A. Fasching, Mark T. Goodman, Beth Y. Karlan, Francesmary Modugno, Kirsten B. Moysich, Roberta B. Ness, Weiva Sieh, Paul D. Pharoah, Susan J. Ramus, Ellen L. Goode. Tumor-infiltrating CD8-positive T-lymphocytes in tubo-ovarian high-grade serous cancer are associated with multiple germline variants in 22q12.1 in a genome-wide association analysis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 225.
Abstract 224: Evidence for a shared genetic basis between breast cancer and mammographic density phenotypes
Chen, Hongjie , Douglas, Julie A. , Gordon, William, Thompson, Deborah J. , Fasching, Peter A. , Maskarenic, Gertraud, Lindströem, Sara, Couch, Fergus J. , Hall, Per N , Hopper, John L. , Pollán, Marina , Stone, Jennifer , Tamimi, Rulla M.

Mayo Clinic

Cancer Research | August 17, 2018 | Volume: 78 | Issue: 13_Supplement | Pages: 224-224

10.1158/1538-7445.am2018-224 Get It

Abstract Background: Radiologically dense area (DA) on a mammogram represents the stromal and epithelial tissue in the breast, while non-dense area (NDA) represents adipose tissue. Quantitative measurements of DA, NDA as well as the proportion of dense area in the breast (percent density, PD) adjusted for age and body mass index (BMI) have all been associated with breast cancer (BC) risk. Previous genome-wide association studies (GWAS) have identified genetic loci that show association with both mammographic density (MD) phenotypes and BC, but little is known about the genome-wide and local genetic correlation between MD phenotypes and BC. Methods: We estimated the genome-wide and local genetic correlation between MD phenotypes adjusted for age and BMI and BC, leveraging GWAS summary statistics for MD phenotypes based on 12,866 women (MODE consortium) and for BC based on 122,977 cases and 105,974 controls (BCAC consortium). We also conducted partitioned heritability analysis to identify specific functional annotations that contribute to MD heritability. Results: We observed a negative genetic correlation between DA and NDA (-0.62, p=0.002). Both DA and PD showed positive genetic correlations with overall BC (DA: rg=0.24, p=0.004; PD: rg=0.27, p=0.0001), estrogen receptor-positive (ER+) BC (DA: rg=0.23, p=0.005; PD: rg=0.23, p=0.001), and ER- BC (DA: rg=0.26, p=0.01; PD: rg=0.32, p=0.0006). In contrast, NDA showed a nonsignificant negative genetic correlation with BC (rg=-0.11, p=0.21). Local genetic correlation analyses between MD phenotypes and BC reflected known findings including positive correlation at 10q21 region between both PD and DA and BC (both p<5x10-7), negative correlation at 22q13.1 between DA and BC (p=4.6x10-6), and positive correlation at 8p11.23 between NDA and BC (p=2.8x10-6). Two known BC regions that have not previously been associated with MD showed suggestive genetic correlations between BC and DA: 1q21.2 (negative genetic correlation, p=1.3x10-4) and 12q21.31 (positive genetic correlation, p=6.7x10-4). In exploratory analyses estimating the genome-wide genetic correlation between MD and hormone-related phenotypes in UK Biobank (n=337,199), we observed nominally significant positive genetic correlations between PD and benign mammary dysplasia (rg=0.45, p=0.01), NDA and endometriosis (rg=0.45, p=0.02), and negative genetic correlation between NDA and menstrual cycle length (rg=-0.30, p=0.05). We identified multiple functional annotations that contribute to MD heritability including histone mark H3K27ac that marks active enhancers (~2,5-fold enrichment in heritability for both DA and NDA) and DNAsel Hypersensitive Sites (DHS, 9.1-fold enrichment in heritability for DA). Conclusion: Our results provide evidence of shared genetic basis between mammographic density and breast cancer. Citation Format: Hongjie Chen, Julie Douglas, William Gordon, Deborah Thompson, Fergus Couch, Peter Fasching, Per Hall, John Hopper, Gertraud Maskarenic, Marina Pollan, Jennifer Stone, Rulla Tamimi, Sara Lindstroem. Evidence for a shared genetic basis between breast cancer and mammographic density phenotypes [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 224.
Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study
Rambau, Peter , Vierkant, Robert A. , Intermaggio, Maria P., Kelemen, Linda E. , Goodman, Marc T. , Herpel, Esther , Kommoss, Stefan , Jimenez‐Liñan, Mercedes , Menon, Usha , Polo, Susanna Hernando, Reis, Francisco José Cândido dos , Gayther, Simon A. , Sharma, Raghwa , Harnett, Paul R. , Hatfield, Emma, Andrade, Jurandyr Moreira de , Nelson, Gregg , Steed, Helen , Schildkraut, Joellen M. , Carney, Micheal E, Høgdall, Estrid , Whittemore, Alice S. , Widschwendter, Martin , Kennedy, Catherine J. , Armasu, Sebastian M. , Daley, Frances , Coulson, Penny , Jones, Michael E. , Anglesio, Michael S. , Chow, Christine , Fazio, Anna de , García‐Closas, Montserrat , Huzarski, Tomasz , Jensen, Allan , Lubiński, Jan , Oszurek, Oleg, Benı́tez, Javier , Mina, Fady , Staebler, Annette , Taran, Florin‐Andrei , Pasternak, J , Talhouk, Aline , Rossing, Mary Anne, Hendley, Joy , Group, AOCS, Fereday, Sián , Ness, Roberta B., Sieh, Weiva , El‐Bahrawy, Mona , Lester, Jenny , Sinn, Hans‐Peter , Fasching, Peter A. , Chang‐Claude, Jenny , Moysich, Kirsten B. , Bowtell, David D.L. , Luk, Hugh, Shah, Mitul , Jung, Audrey , Alsop, Jennifer , Thompson, Pamela J., Swerdlow, Anthony J. , Karpinskyj, Chloe , García, María J. , Deen, Susha, Palacios, José , Koziak, Jennifer M. , Goode, Ellen L. , Huntsman, David G. , Ramus, Susan J. , Köbel, Martin , DeFazio, Anna , Köbel, Martin , Ramus, Susan J , Jensen, Allan , Vierkant, Robert A , Menon, Usha , Swerdlow, Anthony J , Moysich, Kirsten , Kennedy, Catherine J , Sinn, Peter , Widschwendter, Martin , Anglesio, Michael S , Jones, Michael E , Sieh, Weiva , García-Closas, Montserrat , Benitez, Javier , Høgdall, Estrid , Huzarski, Tomasz , Jung, Audrey Y , Bowtell, David D , Fereday, Sian , Lubinski, Jan , Nelson, Gregg S , El-Bahrawy, Mona A , Harnett, Paul R , Steed, Helen , Goodman, Marc T , Pharoah, Paul D.P. , Karlan, Beth Y. , Gentry‐Maharaj, Aleksandra , Doherty, Jennifer A. , Larson, Melissa C. , Hatfield, Emma, Wang, Frances M. , Wang, Qin , Wang, Chen , Brucker, Sara Yvonne , Cybulski, Cezary , Harris, Holly R. , Hartkopf, Andreas D , Group, AOCS, Edwards, Todd , Modugno, Francesmary , Winham, Stacey J. , Kjær, Susanne K. , Gronwald, Jacek , Hernandez, Brenda Y. , Behrens, Sabine , Ghatage, Prafull , Alsop, Kathryn , García-Donás, Jesús , Cazorla, Alicia , Wilkens, Lynne R. , Berchuck, Andrew , Brenton, James D. , Cook, Linda S.

Mayo Clinic

The Journal of Pathology: Clinical Research | July 30, 2018 | Volume: 4 | Issue: 4 | Pages: 250-261

10.1002/cjp2.109 | PMID 30062862 Get It

AbstractWe aimed to validate the prognostic association of p16 expression in ovarian high‐grade serous carcinomas (HGSC) and to explore it in other ovarian carcinoma histotypes. p16 protein expression was assessed by clinical‐grade immunohistochemistry in 6525 ovarian carcinomas including 4334 HGSC using tissue microarrays from 24 studies participating in the Ovarian Tumor Tissue Analysis consortium. p16 expression patterns were interpreted as abnormal (either overexpression referred to as block expression or absence) or normal (heterogeneous). CDKN2A (which encodes p16) mRNA expression was also analyzed in a subset (n = 2280) mostly representing HGSC (n = 2010). Association of p16 expression with overall survival (OS) was determined within histotypes as was CDKN2A expression for HGSC only. p16 block expression was most frequent in HGSC (56%) but neither protein nor mRNA expression was associated with OS. However, relative to heterogeneous expression, block expression was associated with shorter OS in endometriosis‐associated carcinomas, clear cell [hazard ratio (HR): 2.02, 95% confidence (CI) 1.47–2.77, p < 0.001] and endometrioid (HR: 1.88, 95% CI 1.30–2.75, p = 0.004), while absence was associated with shorter OS in low‐grade serous carcinomas (HR: 2.95, 95% CI 1.61–5.38, p = 0.001). Absence was most frequent in mucinous carcinoma (50%), and was not associated with OS in this histotype. The prognostic value of p16 expression is histotype‐specific and pattern dependent. We provide definitive evidence against an association of p16 expression with survival in ovarian HGSC as previously suggested. Block expression of p16 in clear cell and endometrioid carcinoma should be further validated as a prognostic marker, and absence in low‐grade serous carcinoma justifies CDK4 inhibition.
A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk
Lu, Yingchang , Beeghly‐Fadiel, Alicia, Wu, Lang , Li, Bingshan , Schildkraut, Joellen M. , Im, Hae Kyung , Chen, Y. Ann , Permuth, Jennifer B. , Reid, Brett M. , Teer, Jamie K. , Moysich, Kirsten B., Andrulis, Irene L. , Barkardóttir, Rósa B. , Benı́tez, Javier , Caldés, Trinidad , Chang‐Claude, Jenny , Claes, Kathleen , Daly, Mary B., DeFazio, Anna , Dörk, Thilo , Easton, Douglas F. , Eccles, Diana M., Fasching, Peter A. , Fortner, Renée T. , Fountzilas, George , Friedman, Eitan , Ganz, Patricia A. , Goldgar, David E., Goodman, Marc T. , Greene, Mark H. , Hamann, Ute, Heitz, Florian , Hildebrandt, Michelle A.T., Høgdall, Claus , Hulick, Peter J. , Huntsman, David G. , Imyanitov, Evgeny N., Jakubowska, Anna , James, Paul A. , Kelemen, Linda E., Kwong, Ava , Le, Nhu D., Lesueur, Fabienne , May, Taymaa, McGuffog, Lesley, McNeish, Iain A. , Merritt, Melissa A. , Montagna, Marco , Ņikitina-Zaķe, Liene , Offit, Kenneth, Oláh, Edith , Olopade, Olufunmilayo I. , Olsson, Håkan , Osório, Ana , Park, Sue K. , Peeters, Petra H.M. , Peterlongo, Paolo , Phelan, Catherine M., Pujana, Miguel Ángel , Ramus, Susan J. , Rennert, Gad , Rodriguez, Gustavo C. , Rodríguez‐Antona, Cristina , Romieu, Isabelle , Rookus, Matti A. , Rossing, Mary Anne, Rzepecka, Iwona K. , Schmutzler, Rita K., Sieh, Weiva , Simard, Jacques , Song, Honglin , Sutphen, Rebecca , Swerdlow, Anthony J. , Teixeira, Manuel R. , Teo, Soo‐Hwang , Thomassen, Mads , Trichopoulou, Antonia , Tworoger, Shelley S. , Rensburg, Elizabeth J. van , Vega, Ana , Edwards, Digna Velez, Webb, Penelope M. , Weitzel, Jeffrey N. , Wentzensen, Nicolas , Wu, Anna H. , Zorn, Kristin K. , Gayther, Simon A. , Antoniou, Antonis C. , Goode, Ellen L. , Chenevix‐Trench, Georgia , Sellers, Thomas A. , Long, Jirong , Durocher, Francine , Eccles, Diana , Permuth, Jennifer B , Teer, Jamie K , Barnes, Daniel R , Caldes, Trinidad , Caligo, Maria A , Chang-Claude, Jenny , Fazio, Anna de , Dennis, Joe , Fasching, Peter A , Fortner, Renée T , Garber, J. E. , Giles, Graham G , Greene, Mark H , Hulick, Peter J , Isaacs, Claudine , James, Paul , Kiemeney, Lambertus A , Kjaer, Susanne K , Leslie, Goska , Lesueur, Fabienne , McNeish, Iain A , Nevanlinna, H , Nussbaum, Robert , Park, Sue K , Parsons, Michael T , Peterlongo, Paolo , Pujana, Miquel Angel , Ramus, Susan J , Rennert, Gad , Rodríguez-Antona, Cristina , Sandler, Dale P , Spurdle, Amanda B , Teixeira, Manuel R , Teo, Soo H , Tworoger, Shelley S , van Rensburg, Elizabeth J , Vanderstichele, Adriaan , Webb, Penelope M , Wolk, Alicja , Dörk, Thilo , Eccles, Diana , Swerdlow, Anthony J , Moysich, Kirsten , Vega, Ana , Weitzel, Jeffrey N , Claes, Kathleen B M , Olopade, Olufunmilayo I , Heitz, Florian , Jakubowska, Anna , Sieh, Weiva , Benitez, Javier , Montagna, Marco , Simard, Jacques , Chenevix-Trench, Georgia , Høgdall, Claus K , Goodman, Marc T , Beeghly‐Fadiel, Alicia , Guo, Xingyi , Moysich, Kirsten B. , Anton‐Culver, Hoda , Arun, Banu , Bandera, Elisa V. , Barnes, Daniel R. , Bjørge, Line , Brenton, James D. , Bützow, Ralf C. , Caligo, Maria A. , Campbell, Ian , Couch, Fergus J. , Cramer, Daniel W. , Dı́ez, Orland , Domchek, Susan M. , Garber, Judy E. , Giles, Graham G. , Godwin, Andrew K. , Gronwald, Jacek , Hildebrandt, Michelle A.T. , Hollestelle, Antoinette , Isaacs, Claudine , Karlan, Beth Y. , Kiemeney, Lambertus A. , Kjær, Susanne K. , Leslie, Goska , Levine, Douglas A. , Mattiello, Amalia , Modugno, Francesmary , Neuhausen, Susan L. , Nevanlinna, Heli , Nielsen, Finn Cilius , Nussbaum, Robert L. , Olson, Sara H. , Parsons, Michael T. , Pejovic, Tanja B. , Risch, Harvey A. , Sandler, Dale P. , Setiawan, Veronica Wendy , Sharma, Priyanka , Singer, Christian F. , Southey, Melissa C. , Spurdle, Amanda B. , Tischkowitz, Marc D. , Toland, Amanda Ewart , Tung, Nadine , Vanderstichele, Adriaan , Edwards, Digna R. Velez , White, Emily , Wolk, Alicja , Yannoukakos, Drakoulis , Berchuck, Andrew , Pharoah, Paul D.P. , Zheng, Wei , Kwong, Ava , Im, H K

Mayo Clinic

Cancer Research | July 27, 2018 | Volume: 78 | Issue: 18 | Pages: 5419-5430

10.1158/0008-5472.can-18-0951 | PMID 30054336 Get It

Abstract Large-scale genome-wide association studies (GWAS) have identified approximately 35 loci associated with epithelial ovarian cancer (EOC) risk. The majority of GWAS-identified disease susceptibility variants are located in noncoding regions, and causal genes underlying these associations remain largely unknown. Here, we performed a transcriptome-wide association study to search for novel genetic loci and plausible causal genes at known GWAS loci. We used RNA sequencing data (68 normal ovarian tissue samples from 68 individuals and 6,124 cross-tissue samples from 369 individuals) and high-density genotyping data from European descendants of the Genotype-Tissue Expression (GTEx V6) project to build ovarian and cross-tissue models of genetically regulated expression using elastic net methods. We evaluated 17,121 genes for their cis-predicted gene expression in relation to EOC risk using summary statistics data from GWAS of 97,898 women, including 29,396 EOC cases. With a Bonferroni-corrected significance level of P &lt; 2.2 × 10−6, we identified 35 genes, including FZD4 at 11q14.2 (Z = 5.08, P = 3.83 × 10−7, the cross-tissue model; 1 Mb away from any GWAS-identified EOC risk variant), a potential novel locus for EOC risk. All other 34 significantly associated genes were located within 1 Mb of known GWAS-identified loci, including 23 genes at 6 loci not previously linked to EOC risk. Upon conditioning on nearby known EOC GWAS-identified variants, the associations for 31 genes disappeared and three genes remained (P &lt; 1.47 × 10−3). These data identify one novel locus (FZD4) and 34 genes at 13 known EOC risk loci associated with EOC risk, providing new insights into EOC carcinogenesis. Significance: Transcriptomic analysis of a large cohort confirms earlier GWAS loci and reveals FZD4 as a novel locus associated with EOC risk. Cancer Res; 78(18); 5419–30. ©2018 AACR.
Genetic variants in FCGR2A and FCGR3A and disease-free survival in patients with HER2 positive breast cancer treated with trastuzumab in the SUCCESS A trial
Wunderle, Marius , Rack, Brigitte , Häberle, Lothar , Lux, MP, Cunningham, JM, Rübner, Matthias, Schneeweiß, Andreas , Tesch, Hans , Heinrich, G. , Rezai, Mahdi , Beckmann, MW, Janni, Wolfgang , Weinshilboum, RM, Wang, L, Fasching, PA, Hein, Alexander , Li, Lei , Ekici, Arif B. , Reis, André , Blohmer, Jens‐Uwe , Fehm, Tanja

Mayo Clinic

Senologie - Zeitschrift für Mammadiagnostik und -therapie | July 5, 2018 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0038-1651824 Get It

Genetic overlap between endometriosis and endometrial cancer: evidence from cross‐disease genetic correlation and GWAS meta‐analyses
Painter, Jodie N. , O’Mara, Tracy A. , Morris, Andrew P. , Cheng, Timothy, Gorman, Maggie, Martin, Lynn , Hodson, Shirley, Henders, Anjali K. , McEvoy, Mark , Holliday, Elizabeth , Scott, Rodney J. , Webb, Penelope M. , Fasching, Peter A. , Beckmann, Matthias W. , Ekici, Arif B. , Hein, Alexander , Rübner, Matthias, Dörk, Thilo , Hillemanns, Peter , Runnebaum, Ingo B. , Lambrechts, Diether , Annibali, Daniela , Depreeuw, Jeroen, Goode, Ellen L. , Cunningham, Julie M. , Dowdy, Sean C. , Trovik, Jone , Høivik, Erling A. , Werner, Henrica M.J., Krakstad, Camilla , Ashton, Katie A. , Otton, Geoffrey, Proietto, Tony, Tham, Emma , Mints, Miriam, Healey, Catherine S., Shah, Mitul , Bolla, Manjeet K. , Michailidou, Kyriaki , Wang, Qin , Hopper, John L. , Peto, Julian , Swerdlow, Anthony J. , Burwinkel, Barbara , Brenner, Hermann , Meindl, Alfons, Brauch, Hiltrud , Lindblom, Annika , Chang‐Claude, Jenny , Couch, Fergus J. , Kristensen, Vessela N. , Zondervan, Krina T. , Nyholt, Dale R. , MacGregor, Stuart , Tomlinson, Ian , Easton, Douglas F. , Thompson, Deborah J. , Lambrechts, Diether , Fasching, Peter A , Dörk, Thilo , Lambrechts, Diether , Goode, Ellen L , Webb, Penelope M , Hein, Alexander , Hillemanns, Peter , Swerdlow, Anthony J , O'Mara, Tracy A , Lambrechts, Diether , Brenner, Hermann , Ekici, Arif B , Michailidou, Kyriaki , MacGregor, Stuart , Jones, Angela , Martin, Nicholas G. , Gordon, Scott D. , Attia, John , Hall, Per N , Czene, Kamila , Dürst, Matthias , Amant, Frédéric , Vanderstichele, Adriaan , Winham, Stacey J. , Mints, Miriam , Ahmed, Shahana , Pharoah, Paul D.P. , Dunning, Alison M. , Dennis, Joe , Tyrer, Jonathan P. , Meindl, Alfons, Couch, Fergus J. , Giles, Graham G. , Cox, Angela , Montgomery, Grant W. , Spurdle, Amanda B. , Brauch, Hiltrud , Lindblom, Annika

Mayo Clinic

Cancer Medicine | April 2, 2018 | Volume: 7 | Issue: 5 | Pages: 1978-1987

10.1002/cam4.1445 | PMID 29608257 Get It

AbstractEpidemiological, biological, and molecular data suggest links between endometriosis and endometrial cancer, with recent epidemiological studies providing evidence for an association between a previous diagnosis of endometriosis and risk of endometrial cancer. We used genetic data as an alternative approach to investigate shared biological etiology of these two diseases. Genetic correlation analysis of summary level statistics from genomewide association studies (GWAS) using LD Score regression revealed moderate but significant genetic correlation (rg = 0.23, P = 9.3 × 10−3), and SNP effect concordance analysis provided evidence for significant SNP pleiotropy (P = 6.0 × 10−3) and concordance in effect direction (P = 2.0 × 10−3) between the two diseases. Cross‐disease GWAS meta‐analysis highlighted 13 distinct loci associated at P ≤ 10−5 with both endometriosis and endometrial cancer, with one locus (SNP rs2475335) located within PTPRD associated at a genomewide significant level (P = 4.9 × 10−8, OR = 1.11, 95% CI = 1.07–1.15). PTPRD acts in the STAT3 pathway, which has been implicated in both endometriosis and endometrial cancer. This study demonstrates the value of cross‐disease genetic analysis to support epidemiological observations and to identify biological pathways of relevance to multiple diseases.
The BRCA2 c.68-7T > A variant is not pathogenic: A model for clinical calibration of spliceogenicity
Colombo, Mara , López‐Perolio, Irene, Caleca, Laura , Li, Hongyan , Vecchi, Giovanna De, Tudini, Emma , Foglia, Claudia , Mondini, P, Manoukian, Siranoush , Behar, Raquel, Gómez, E. , Meindl, Alfons, Montagna, Marco , Niederacher, Dieter , Schmidt, Ane Yde , Varesco, Liliana , Wappenschmidt, Barbara , Bolla, Manjeet K. , Michailidou, Kyriaki , Wang, Qin , Aittomäki, Kristiina, Andrulis, Irene L. , Beckmann, Matthias W. , Beeghly-Fadel, Alicia, Benı́tez, Javier , Bojesen, Stig E. , Bonanni, Bernardo, Brauch, Hiltrud , Brenner, Hermann , Burwinkel, Barbara , Chang‐Claude, Jenny , Conroy, Don, Eriksson, Mikael , Fasching, Peter A. , Figueroa, Jonine D. , Fletcher, Olivia , Flyger, Henrik, Gabrielson, Marike , García‐Closas, Montserrat , González‐Neira, Anna , Guénel, Pascal , Haiman, Christopher A., Hamann, Ute , Hartman, Mikael , Hauke, Jan , Hopper, John L. , Jakubowska, Anna , Kosma, Veli‐Matti , Lambrechts, Diether , Marchand, Loid Le, Lindblom, Annika , Lubiński, Jan , Mannermaa, Arto, Margolin, Sara , Miao, Hui, Peterlongo, Paolo , Peto, Julian , Pylkäs, Katri , Sawyer, Elinor J. , Schmutzler, Rita K., Schneeweiß, Andreas , Schoemaker, Minouk J. , See, Mee‐Hoong , Southey, Melissa C. , Swerdlow, Anthony J. , Teo, Soo‐Hwang , Tomlinson, Ian , Truong, Thérèse , Ouweland, Ans M.W. van den, Kolk, Lizet E. van der, Winqvist, Robert , Zheng, Wei , Investigators, kConFab/AOCS, Easton, Douglas F. , Henderson, Alex, Hogervorst, Frans B.L., Izatt, Louise, Offitt, Kenneth, Side, Lucy, Rensburg, Elizabeth J. van , EMBRACE, Study, HEBON, Study, McGuffog, Lesley, Antoniou, Antonis C. , Chenevix‐Trench, Georgia , Goldgar, David E., Hoya, Miguel de la , Radice, Paolo , Bowtell, David D.L. , Lambrechts, Diether , Lambrechts, Diether , Peterlongo, Paolo , Teo, Soo H , van Rensburg, Elizabeth J , Swerdlow, Anthony J , de la Hoya, Miguel , Radice, Paolo , Southey, Melissa C , Jakubowska, Anna , Lambrechts, Diether , Brenner, Hermann , Guénel, Pascal , Hartman, Mikael , García-Closas, Montserrat , Michailidou, Kyriaki , Benitez, Javier , Montagna, Marco , Chenevix-Trench, Georgia , Zheng, Wei , Eriksson, Mikael , Figueroa, Jonine D , Gabrielson, Marike , Bowtell, David D , Meeks, Huong , Parsons, Michael T. , Meindl, Alfons, Dennis, Joe , Anton‐Culver, Hoda , Arndt, Volker , Boeckx, Bram , Bogdanova, Natalia , Bonanni, Bernardo , Couch, Fergus J. , Cox, Angela , Cross, Simon S. , Czene, Kamila , Devilee, Peter , Dörk, Thilo , Giles, Graham G. , Hall, Per N , Hollestelle, Antoinette , Jung, Audrey , Mannermaa, Arto , Miao, Hui, Milne, Roger L. , Neuhausen, Susan L. , Nevanlinna, Heli , Olson, Janet E. , Schmidt, Marjanka K. , Toland, Amanda Ewart , Asperen, Christi J. van , Yannoukakos, Drakoulis , Investigators, kConFab/AOCS, Dunning, Alison M. , Spurdle, Amanda B. , Goldgar, David E., Pylkäs, Katri , Gómez-García, Encarna B , Hauke, Jan , Manoukian, Siranoush , Lubinski, Jan , Fletcher, Olivia , Bojesen, Stig E , Schoemaker, Minouk J , Truong, Therese , Brauch, Hiltrud , Lindblom, Annika , Sawyer, Elinor J

Mayo Clinic

Human Mutation | February 21, 2018 | Volume: 39 | Issue: 5 | Pages: 729-741

10.1002/humu.23411 | PMID 29460995 Get It

Abstract PD1-02: Cancer predisposition genes in metastatic breast cancer – Association with metastatic pattern, prognosis, patient and tumor characteristics
Fasching, PA, Hart, SN, Polley, EC, Lee, KY, Gnanolivu, RD, Lilyquist, Jenna , Hartkopf, AD, Taran, FA, Janni, Wolfgang , Hadji, Peyman , Tesch, Hans , Haeberle, Lothar, Ettl, Johannes , Lux, MP, Lueftner, Diana, Müller, Volkmar , Beckmann, MW, Belleville, Erik, Kolberg, H-C, Fehm, TN, Overkamp, Friedrich , Wallwiener, D. , Brucker, SY, Schneeweiß, Andreas , Hu, C, Wallwiener, Markus , Wimberger, Pauline , Untch, Michael , Couch, Fergus J.

Mayo Clinic

Cancer Research | February 15, 2018 | Volume: 78 | Issue: 4_Supplement | Pages: PD1-02-PD1-02

10.1158/1538-7445.sabcs17-pd1-02 Get It

Abstract Background New treatment strategies for metastatic breast cancer (mBC) are mainly driven by therapies against specific targets. BRCA mutations are one of the few established actionable targets, with PARP-Inhibitors and Platinum showing high efficacy in mBC. Hereditary cancer testing panels are now broadly used for identification of individuals with BRCA1/2 mutations who may benefit from these therapies. Many of these panels also contain other predisposition genes involved in BRCA-related DNA repair pathways, but the clinical relevance of mutations in these genes remain unclear. The aim of this study was to describe the mutation rates of BRCA1/2 and panel-based predisposition genes, and the associated clinical characteristics of individuals with these mutations, in a prospective cohort of mBC patients. Methods The PRAEGNANT mBC registry (NCT02338167) is a prospective registry for metastatic breast cancer patients with a focus on molecular biomarkers. Patients receiving any therapeutic regimen are eligible for this registry. Germline DNA was collected at study entry and genotyped for 37 cancer predisposition genes including BRCA1 and BRCA2. The frequency of mutations in each gene was determined, and associations between mutations and patient and tumor characteristics, metastatic pattern, and overall survival were assessed. Results Mutations in established high (odds ratio (OR)&gt;5.0) and moderate risk (OR&gt;2.0) breast cancer genes (BRCA1/2, PALB2, CHEK2, ATM, RAD51D, BARD1, and MSH6) were seen in 123 of 1462 tested patients with mBC (8.4%). BRCA1 and BRCA2 mutations were seen in 1.4% and 2.9% of patients respectively. Most frequently mutated non-BRCA panel genes were CHEK2, PALB2 and ATM with 2.8%, 0.8% and 0.6% of patients. Mutation frequency varied with regard to patients who developed brain metastases, visceral metastases or bone only metastases. BRCA1 or BRCA2 mutations were seen frequently in patients with brain (5.3%) or visceral metastases (5.2%), but were present in only 2.5% patients with bone only metastases and 1.5% of patients with lesions in other locations. Panel genes were equally distributed among all metastatic patients. PALB2 mutations (n=11) were only seen in patients with brain (1.9%) and visceral metastases (0.9%), but not in patients with bone metastases or other locations. 36.4% (N=4) of all patients with PALB2 mutations developing a brain metastasis. When adjusted for other mBC prognostic factors, a mutation (all genes) was associated with an unfavorable prognosis (HR: 1.50; 95%CI: 1.04 to 2.30, p=0.03). Mutation frequencies were similar according to therapy lines. All other associations with molecular subtypes and risk factors were similar to primary breast cancer cases. Conclusion Mutations in high and moderate risk breast cancer genes were frequent in metastatic breast cancer patients. The frequency was substantially higher than the 4 to 5% mutation frequency observed among unselected primary breast cancer patients, but is consistent with recent results from studies of metastatic prostate cancer patients. Patients with brain and visceral metastases had the highest BRCA mutation rates. Results suggested that PALB2 mutations may be more frequent in patients with brain metastases. Citation Format: Fasching PA, Hu C, Hart SN, Polley EC, Lee KY, Gnanolivu RD, Lilyquist J, Hartkopf AD, Taran FA, Janni W, Hadji P, Tesch H, Haeberle L, Ettl J, Lux MP, Lueftner D, Wallwiener M, Mueller V, Beckmann MW, Belleville E, Wimberger P, Untch M, Kolberg H-C, Fehm TN, Overkamp F, Wallwiener D, Brucker SY, Schneeweiss A, Couch F. Cancer predisposition genes in metastatic breast cancer – Association with metastatic pattern, prognosis, patient and tumor characteristics [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr PD1-02.
PHIP- a novel candidate breast cancer susceptibility locus on 6q14.1
Jiao, Xiang , Collaborators, NBCS, Investigators, kConFab/AOCS, Aravidis, Christos , Marikkannu, Rajeshwari, Rantala, Johanna, Adamović, Tatjana , Maguire, Paula , Kremeyer, Bárbara , Holst, Susanna von, Kontham, Vinaykumar, Thutkawkorapin, Jessada , Margolin, Sara , Du, Quan , Lundin, Johanna , Michailidou, Kyriaki , Bolla, Manjeet K. , Wang, Qin , Andrulis, Irene L. , Antonenkova, Natalia, Beckmann, Matthias W. , Blomqvist, Carl , Blot, William J. , Bojesen, Stig E. , Brand, Judith S. , Brauch, Hiltrud , Brenner, Hermann , Brüning, Thomas , Burwinkel, Barbara , Chang‐Claude, Jenny , Couch, Fergus J. , Deming-Halverson, Sandra, Dörk, Thilo , Eriksson, Mikael , Fasching, Peter A. , Figueroa, Jonine D. , Flesch‐Janys, Dieter, Flyger, Henrik, Gabrielson, Marike , García‐Closas, Montserrat , González‐Neira, Anna , Guénel, Pascal , Guo, Qi , Gündert, Melanie , Haiman, Christopher A., Hallberg, Emily, Hamann, Ute , Harrington, Patricia, Hooning, Maartje J. , Hopper, John L. , Huang, Guanmengqian, Jakubowska, Anna , Jones, Michael E. , Kerin, Michael J. , Kosma, Veli‐Matti , Kristensen, Vessela N. , Lambrechts, Diether , Lubiński, Jan , Mannermaa, Arto, Meindl, Alfons, Mulligan, Anna Marie , Peto, Julian, Pylkäs, Katri , Radice, Paolo , Rhenius, Valerie , Sawyer, Elinor J. , Schmutzler, Rita K., Seynaeve, Caroline, Shah, Mitul , Simard, Jacques , Southey, Melissa C. , Swerdlow, Anthony J. , Truong, Thérèse , Wendt, Camilla, Winqvist, Robert , Easton, Douglas F. , Lindblom, Annika , Durocher, Francine , Bowtell, David D.L. , Lambrechts, Diether , Dörk, Thilo , Lambrechts, Diether , Swerdlow, Anthony J , Radice, Paolo , Southey, Melissa C , Jakubowska, Anna , Jones, Michael E , Lambrechts, Diether , Brenner, Hermann , Guénel, Pascal , García-Closas, Montserrat , Michailidou, Kyriaki , Simard, Jacques , Eriksson, Mikael , Figueroa, Jonine D , Gabrielson, Marike , Bowtell, David D , Collaborators, NBCS, Investigators, kConFab/AOCS, Picelli, Simone , Liu, Tao , Luo, Liping , Dennis, Joe , Lush, Michael J. , Ambrosone, Christine B. , Anton‐Culver, Hoda , Arndt, Volker , Boeckx, Bram , Bonanni, Bernardo , Broeks, Annegien , Cai, Qiuyin , Couch, Fergus J. , Cox, Angela , Cross, Simon S. , Devilee, Peter , dos‐Santos‐Silva, Isabel , Giles, Graham G. , Hooning, Maartje J. , Marchand, Loı̈c Le , Mannermaa, Arto, Martens, John W.M. , Meindl, Alfons, Milne, Roger L. , Neuhausen, Susan L. , Nevanlinna, Heli , Schmidt, Marjanka K. , Zheng, Wei , Benı́tez, Javier , Dunning, Alison M. , Pharoah, Paul D.P. , Czene, Kamila , Hall, Per N , Pylkäs, Katri , Lubinski, Jan , Bojesen, Stig E , Truong, Therese , Brauch, Hiltrud , Lindblom, Annika , Sawyer, Elinor J

Mayo Clinic

Oncotarget | December 7, 2017 | Volume: 8 | Issue: 61 | Pages: 102769-102782

10.18632/oncotarget.21800 | PMID 29262523 Get It